Botulinum Neurotoxin Type A
Phase 2Small molecule
Botulinum Neurotoxin Type A is one of 70 small molecule programs targeting Cerebral Palsy. It is currently in Phase 2.
3
Indications
6
Total Trials
3
Active Trials
69
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
82 competitors in Cerebral Palsy
#DrugCompanyPhaseTrials
1Ingrezza
Neurocrine BiosciencesPhase 3
XEOMIN
MMerz Pharmaceuticals GmbH
Phase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Advil
KKenvue Brands
Phase 3
Cyklokapron
AAmring
Phase 3
Dysport
IpsenPhase 3
Botulinum Toxin
MMeshalkin Research Institute of Pathology of Circulation
Phase 3
Fosamax
Mylan Pharmaceuticals IncPhase 3
PROCRIT
WWim Janssens
Phase 2
Osmitrol
BB. Braun Medical Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Spasticity1 trial
Effectiveness of an Interprofessional Approach to the Treatment of Spasticity With Botulinum Toxin & Non-pharmacological Therapies
Not yet recruiting·—·N/A·NCT07160699·30 enrolled
Treatment1 trial
Study of the Drug B11-FC (Botulism Treatment)
Not yet recruiting·GGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation·Phase 1/2·NCT06580236·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Botulinum Neurotoxin Type A. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- DDeNova Research